CLDN18 and cancer: A functional study conducted by Yao et al. suggested that introducing CLDN18- ARHGAP26 fusion to tumor cells can result in the loss of epithelial phenotype, EMT, and inhibition of the RhoA signaling pathway, thereby contributing to tumor invasiveness in cancer cell lines [89].